Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Advanced Melanoma. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.

Published in Advanced Melanoma

Expert Opinion / Cases · May 11, 2022

A Different Kind of BRAF Mutation — BRAF/MEKi or Follow-Up?

Written by
Viola Franke MD


Additional Info

Disclosure statements are available on the authors' profiles:

Discuss This item Follow

No comments yet, be the first to start the discussion!

  • Galina Kharkevich

    May 13, 2022


  • Svetlana Protsenko

    May 16, 2022

    Follow up

  • Ankit Mangla

    Oct 16, 2022

    Resection of in-transit mets +/- discussion for complete lymph node dissection (if PET positive). Restaging PET scan and MRI brain. If all are negative, then follow up in the clinic as per the protocol of IIIC melanoma. Unfortunately, the adjuvant trials were done on patients who had upfront complete lymph node dissection. MSLT-2 criteria changed the surgical practice from complete lymph node dissection to SNLB and US-guided monitoring. 

  • Jul 19, 2024

    Pending Moderator approval.

Further Reading